Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Download Module 1 Slides
    Download Module 2 Slides
    Download Module 1, Clinical Summary
    Download Module 2, Clinical Summary
    Download Module 1 Slides
    Download Module 2 Slides
    Download Module 1 Slides
    Download Module 2 Slides
    Download Module 1 Slides
    Download Module 2 Slides
    Download Module 1 Slides
    Download Module 2 Slides
    Download Module 1 Slides
    Download Module 2 Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Helena Yu

    Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dr Helena Yu is an associate attending and the research director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY, USA. read more

    In addition to her role as a practising medical oncologist, Dr Yu is a clinical and translational researcher with a focus on improving the survival of patients with EGFR-mutant lung cancers. She oversees the research programme for EGFR-mutant lung cancers at MSK, which includes developing effective new therapies for lung cancer, identifying biomarkers for targeted treatments, lineage plasticity and adaptive mutagenesis as pathways of resistance to targeted therapy, and establishing risk-adaptive treatment strategies that tailor treatment to patients based on risk. Dr Yu has established several mechanisms of resistance to first- and third-generation EGFR tyrosine kinase inhibitors and reported on the prognostic significance of concurrent alterations in EGFR-mutant lung cancer seen on next-generation sequencing. 

    Dr Yu has been the principal investigator of 30 clinical trials, including 10 investigator-initiated trials, focused on EGFR-mutant lung cancer.

    Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
    Dr Antonio Passaro

    European Institute of Oncology, Milan, Italy

    Dr Antonio Passaro is a medical oncologist and currently holds the position of senior staff physician at the Division of Thoracic Oncology, European Institute of Oncology in Milan, Italy. read more

    Dr Passaro is a global authority and leader in lung cancer research and clinical practice. His main areas of research and clinical interest are predictive biomarkers, in particular EGFR and related targeted and immunotherapy agents, from discovery to validation in the clinical setting. He is also highly involved in the use of targeted agents in non-metastatic settings, either alone, or in a multimodality approach, for early or locally-advanced disease. 

    Dr Passaro is involved in a portfolio of many clinical trials, both industry-funded and academic, investigating a range of novel lung cancer therapies. He has published more than 120 articles in peer-reviewed journals. He also serves as a member of several national and international scientific committees. Notably, he has authored guidelines for ESMO (European Medical Society for Medical Oncology) and AIOM (Italian Association of Medical Oncology), guiding the management and treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).

    Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
    Dr Aaron Lisberg

    University of California, Los Angeles (UCLA), Los Angeles, CA, USA

    Dr Aaron Lisberg is a thoracic medical oncologist at the University of California, Los Angeles (UCLA), USA.  read more

    Dr Lisberg specializes in novel drug development, antibody–drug conjugates (ADCs), immunotherapy and metabolically-targeted therapies in patients with advanced malignancies, with a focus on lung cancer. He is board-certified in haematology and medical oncology.

    Dr Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies and has a wide range of ongoing research projects, including the evaluation of factors predictive of response or toxicity to ADCs and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumour alterations. He is also the clinical principal investigator and sub-investigator of several clinical trials evaluating novel therapeutics in various malignancies, including phase I, II and III assessments.

    Dr Aaron Lisberg discloses: Advisory board or panel speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Grants/research support from AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics and WindMIL Therapeutics, Inc.
    Dr Sara Pilotto

    University of Verona, Verona, Italy

    Dr Sara Pilotto is a medical oncologist and associate professor at the University of Verona in Verona, Italy. read more

    Dr Pilotto completed her graduate studies and residency in medical oncology at the University of Verona and trained in the Translational Research Unit at the Pangaea Biotech laboratory, Quiron-Dexeus University Hospital in Barcelona, Spain. In 2019, she completed her PhD in Inflammation, Immunity and Cancer at the University of Verona in Italy.

    Dr Pilotto leads the clinical and research team dedicated to thoracic malignancies at the University of Verona, as well as the FORCE (Focus on Research and Care) team, an integrated group dedicated to a comprehensive approach to patients with cancer (with a specific focus on nutrition and physical activity).

    Dr Pilotto is a member of the Lung Cancer Guidelines Experts Panel of a Italian Association of Medical Oncology (AIOM) and a member of the European Society of Medical Oncology (ESMO) Leadership Program 2019.

    Dr Sara Pilotto discloses: Advisory board/panel speaker fees from Amgen, Astrazeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda. Consultancy fees from Boehringer Ingelheim. Speaker’s bureau fees from Amgen, Astrazeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda.
    touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Rare Diseases

    EU Partner

    An Introduction to Rare Diseases

    Rare cancers encompass a diverse group of malignancies that individually affect a limited number of patients. These diseases, while individually rare, collectively impact a significant portion of the population. 

    Current treatments often face challenges due to limited research and understanding, resulting in a lack of standardized therapeutic approaches. However, recent advancements in oncology have sparked a renewed focus on these less common malignancies. Precision medicine, immunotherapies, and targeted therapies are emerging as promising avenues, tailoring treatments to the specific genetic and molecular characteristics of each rare cancer.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Rare Diseases Content

    Haematology, Rare Diseases
    Watch Time: 64 mins
    touchCLINICAL PERSPECTIVES
    Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
    CE/CME ACCREDITED Dr Helena Yu, Dr Antonio Passaro, Dr Aaron Lisberg, Dr Sara Pilotto Translations available:

    Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.

    Learning objectives
    Learning Objectives
    • Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
    • Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes
    Haematology, Rare Diseases
    Watch Time: 51 mins
    touchCONGRESS
    Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
    CE/CME ACCREDITED Dr Vickie McDonald, Prof. Waleed Ghanima, Prof. James B Bussel Translations available:

    Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.

    Learning objectives
    Learning Objectives
    • Recognize the impact of ITP on patients and their quality of life
    • Appraise the latest data for current chronic ITP treatments and how they may be applied to clinical practice to optimize patient outcomes
    • Evaluate the latest data for emerging chronic ITP therapies and their potential to impact patient outcomes
    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup